dimethyl-4-(3'-nitrophenyl)-pyridine-3-(-methoxyethyl ester)-5-(isopropyl ester) in admixture with a solid or liquefied gaseous diluent or in admixture with a liquid diluent other than a solvent of a molecular weight less than 200 except in the presence of a surface-active agent.

12. A pharmaceutical composition of Claim 11 in the form of a sterile or isotonic aqueous solution.

13. A pharmaceutical composition according to Claim 11 or 12 containing from 0.1 to 90% of the active compound, by weight of the total composition.

14. A composition according to Claim 13 containing from 0.5 to 90% of the compound, by weight of the total composition.

15. A medicament of Claim 14 in the form of tablets, pills, dragees, capsules, ampoules or suppositories.

~~16.~~ A method of combating pathologically reduced cerebral functions and performance weaknesses, cerebral insufficiency and disorders in cerebral circulation and metabolism in warm-blooded animals which comprises administering to the said animals a cerebral specific effective amount for treating said conditions of ~~an active compound as defined in Claim 11~~ either alone or in admixture with a diluent or in the form of a medicament.

~~17.~~ A method according to Claim ~~15~~ in which the active compound is administered intravenously in an amount of 0.0001 to 0.5 mg per kg body weight per day, or enterally in an amount of 0.001 to 1 mg per kg body weight per day.

~~18.~~ A method according to Claim ~~16~~ in which the compound is administered intravenously in an amount of 0.001 to 0.1 mg per kg body weight per day, or enterally in an amount of 0.01 to 0.5 mg per kg body weight per day.

~~19.~~ A method according to Claim ~~16~~ or ~~17~~ in which the active compound is administered orally.

End

14